-
公开(公告)号：US20210187113A1
公开(公告)日：2021-06-24
申请号：US17129376
申请日：2020-12-21
发明人： Thomas Carl Hunter , Randall J. Mrsny , Weijun Feng , Tahir Mahmood , Charles Olsen , Sally Postlethwaite
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20230158163A1
公开(公告)日：2023-05-25
申请号：US17868077
申请日：2022-07-19
CPC分类号： A61K47/6415 , A61K47/65 , A61K9/0043 , A61K9/007 , A61K38/21 , A61K38/27
摘要： The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.
-
公开(公告)号：US11504433B2
公开(公告)日：2022-11-22
申请号：US17129376
申请日：2020-12-21
发明人： Thomas Carl Hunter , Randall J. Mrsny , Weijun Feng , Tahir Mahmood , Charles Olson , Sally Postlethwaite
IPC分类号： A61K47/64 , C07K14/195 , A61K39/10 , A61K39/02
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20220275029A1
公开(公告)日：2022-09-01
申请号：US17673603
申请日：2022-02-16
发明人： Randall J. MRSNY , Derek MACLEAN , Michael SEKAR , Kevin YIN , Tahir Mahmood , Thomas Carl Hunter , Keyi Liu
摘要： The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.
-
公开(公告)号：US11324833B2
公开(公告)日：2022-05-10
申请号：US16884456
申请日：2020-05-27
发明人： Randall J. Mrsny , Charles Olson , Sally Postlethwaite , Thomas Carl Hunter , Tahir Mahmood , Weijun Feng
IPC分类号： A61K39/02 , A61K47/64 , C07K14/28 , C07K14/195
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US20240009316A1
公开(公告)日：2024-01-11
申请号：US18052455
申请日：2022-11-03
发明人： Randall J. Mrsny , Charles Olson , Sally Postlethwaite , Thomas Carl Hunter , Tahir Mahmood , Weijun Feng
IPC分类号： A61K47/64 , C07K14/195 , A61K39/02
CPC分类号： A61K47/6415 , C07K14/195 , A61K39/107
摘要： The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
-
公开(公告)号：US11426466B2
公开(公告)日：2022-08-30
申请号：US17015011
申请日：2020-09-08
摘要： The present disclosure relates to isolated non-naturally occurring delivery constructs comprising a bacterial toxin-derived delivery construct coupled to a biologically active therapeutic cargo; wherein the delivery construct is capable of delivering the biologically active cargo via transcytosis transport across an epithelial cell; and wherein the delivery construct does not comprise a bacterial toxin-derived translocation domain or a bacterial toxin-derived catalytic (cytotoxic) domain.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.015 秒)
